Related Experiment Video
Updated: Jun 5, 2026
06:48
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Blocking IKKα expression inhibits prostate cancer invasiveness
Rubi Mahato1, Bin Qin, Kun Cheng
1Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108, USA.
Pharmaceutical Research
|December 31, 2010
Summary
Silencing IKKα (inhibitor of κB kinase α) with siRNA reduces prostate cancer cell invasion and metastasis. This approach shows promise as a therapeutic strategy for prostate cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- IKKα (inhibitor of κB kinase α) is a key mediator in prostate cancer inflammation and metastasis.
- Targeting IKKα is a potential strategy for managing prostate cancer progression.
Purpose of the Study:
- To silence IKKα expression in prostate cancer cells using synthetic siRNAs.
- To investigate the biological effects of IKKα silencing on tumor cell invasiveness and growth.
Main Methods:
- Designed three synthetic siRNAs targeting IKKα mRNA.
- Determined silencing efficacy in PC-3 and DU145 prostate cancer cell lines.
- Assessed effects on wound healing, migration, invasion, cell attachment, proliferation, and cell cycle.
Main Results:
- Achieved up to 74% silencing of IKKα.
- Inhibition of IKKα significantly reduced prostate cancer cell migration, invasion, and attachment.
- Observed similar anti-invasive effects in the presence of RANKL.
- Found negligible effects on cell proliferation and cell cycle distribution.
Conclusions:
- IKKα is crucial for prostate cancer invasion and metastasis, but not proliferation.
- siRNA-mediated silencing of IKKα presents a potential therapeutic strategy for prostate cancer.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...